

**Boston
Scientific**

Advancing science for life™


ACURATE *neo*™
Aortic Valve System

OPTIMIZING TAVI

TRANSFEMORAL

14F


With iSLEEVE™
Expandable Introducer Set



UNIQUE Self-Expanding
Supra-Annular **VALVE**
TECHNOLOGY

for Transfemoral TAVI





INTUITIVE DESIGN

PREDICTABLE DEPLOYMENT

STRONG CLINICAL OUTCOMES

ACURATE *neo*[™]
Aortic Valve System

INTUITIVE Design

AORTIC VALVE


The unique valve design of ACURATE *neo*[™] provides very high survival rates with excellent hemodynamics and low pacemaker rates.^{1,2}

UPPER CROWN

- Supra-annular anchoring
- Caps native leaflets and provides coronary clearance

LOWER CROWN

- Minimal protrusion into LVOT
- Low risk of conduction system interference



STABILIZATION ARCHES

- Axial self-alignment of valve within the native annulus

SUPRA-ANNULAR VALVE

- Large effective orifice areas and low gradients^{1,2}
- Porcine pericardium leaflets with BioFix[™] anti-calcification process*

ANTI-PVL SKIRT

- Sealing against paravalvular leak

TRANSFEMORAL DELIVERY SYSTEM

With intuitive valve delivery and positioning, ACURATE *neo* minimizes complications and improves procedural efficiency.

FLEXIBLE DELIVERY CATHETER

- Reduced risk of vascular complications
- Full range of ACURATE *neo* valve sizes

14F With iSLEEVE[™]
Expandable Introducer Set



TWO ROTATING KNOBS

- Allow for an uncomplicated step-by-step implantation

SAFETY BUTTON

- Prevents premature implantation

RADIOPAQUE STENT HOLDER

- Reference for positioning

*No clinical data are available which evaluate the long-term impact of the BioFix[™] tissue treatment in patients


PREDICTABLE Deployment

The predictable top-down deployment of ACURATE *neo*[™] delivers the hemodynamic stability and precise placement needed for high procedural success and low rates of complications.^{1,2}




Valve positioning

- Flexible delivery system
- Precise positioning



Top-down deployment

- Co-axial self-alignment
- Hemodynamic stability



Valve release

- Controlled release
- Predictable positioning

STRONG Clinical Outcomes

From early studies establishing safety and efficacy to head-to-head studies that show performance against other valves, ACURATE *neo*[™] continues to undergo rigorous testing and demonstrate outstanding clinical outcomes.

HIGH PROCEDURAL EFFICIENCY¹

98.7%

PROCEDURAL/DEVICE SUCCESS

6:34^{mins}

AVERAGE DEVICE USAGE TIME

FEATURED CLINICAL STUDIES

SAVI-TF Post-Market Registry^{1,2}

0.0%

CORONARY OBSTRUCTION REQUIRING REINTERVENTION*

8.3%

NEW PACEMAKER IMPLANTATION*

MORENA Multicenter Comparison Study: ACURATE *neo* vs. SAPIEN 3³

1.4%

ALL-CAUSE MORTALITY*

*Results at 30 days

STRONG Clinical Outcomes

SAVI-TF Post-Market Registry^{1,2}


REAL-WORLD EXPERIENCE
1,000 PATIENTS

CONFIRMED SAFETY AND PERFORMANCE

- Strong safety and effectiveness data
- Very low complication and pacemaker rates
- Low mortality and excellent hemodynamic performance

SAVI-TF RESULTS SUMMARY


% of patients



HEMODYNAMIC PERFORMANCE

mmHg/cm²

Effective orifice area | Mean transvalvular gradient



* PVL more than mild was observed only in moderately and severely calcified annuli
† at discharge/7 days

MORENA Multicenter Comparison Study

1:2 PROPENSITY-MATCHED MULTICENTER REGISTRY: ACURATE *neo*TM vs. SAPIEN 3TM 3


ACURATE *neo* demonstrated:

- Comparable VARC-2 procedural, performance and safety outcomes
- Lower acute/30-day new permanent pacemaker rates
- Superior hemodynamic performance

PACEMAKER RATE & HEMODYNAMIC PERFORMANCE

% of patients/mmHg

ACURATE *neo* (N = 311) | SAPIEN 3 (N = 622)



COMMITTED to TAVI

As part of our commitment to the structural heart community, Boston Scientific focuses on providing innovative solutions that advance safety in TAVI procedures, help optimize patient outcomes and improve procedural efficiency.

Our differentiated portfolio of TAVI devices – including valves, accessories and a proven cerebral embolic protection device – delivers enhanced control and precision backed by strong clinical evidence and program support.

JOIN US AT
bostonscientific.eu/TAVIportfolio

1. Möllmann H, Hengstenberg C, et al. Real-world experience using the ACURATE *neo* prosthesis: 30-day outcomes of 1,000 patients enrolled in the SAVI-TF registry. *EuroIntervention*. 2018;13:e1764-e1770.
2. Kim W, MD, et al. 1-year outcomes of the European post-market registry using the ACURATE *neo* transcatheter heart valve under real-world conditions in 1,000 patients. *JACC: Cardiovasc Interv*. Vol. 11, no. 14, 2018; July 23, 2018: 1368–74.
3. Husser O, et al. Multicenter Comparison of Novel Self-Expanding versus Balloon-Expandable Transcatheter Heart Valves. *JACC: Cardiovasc Interv*. 10. 2078-2087. 10.1016/j.jcin.2017.06.026.

All cited trademarks are the property of their respective owners. Illustrations for information purposes – not indicative of actual size or clinical outcome. All photographs taken by Boston Scientific. CAUTION: The ACURATE *neo* Aortic Valve System may only be used in countries where it is approved for use. The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for use only in countries with applicable health authority product registrations. Not intended for use or distribution in France, Japan and the USA.

SH-591401-AA

**Boston
Scientific**
Advancing science for life™

bostonscientific.eu/ACURATeneo

© 2019 Boston Scientific Corporation
or its affiliates. All rights reserved.
DINSH0173EA